These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 28495137)
1. Early predictors of rapidly evolving multiple sclerosis: A case report. Fernando KTM; James M J Neuroimmunol; 2017 Jun; 307():42-46. PubMed ID: 28495137 [TBL] [Abstract][Full Text] [Related]
2. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883 [TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
4. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity. Yokote H; Kamata T; Toru S; Sanjo N; Yokota T Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307 [TBL] [Abstract][Full Text] [Related]
5. Brain Lesion Load and Anatomic Distribution in Patients With Juvenile Clinically Isolated Syndrome Predicts Rapidly Advanced to Multiple Sclerosis. Menascu S; Legarda C; Miron S; Achiron A J Child Neurol; 2018 Sep; 33(10):633-638. PubMed ID: 29877125 [TBL] [Abstract][Full Text] [Related]
6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206 [TBL] [Abstract][Full Text] [Related]
8. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Ramo-Tello C; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Grau-López L Mult Scler; 2016 Jan; 22(1):117-21. PubMed ID: 26540732 [TBL] [Abstract][Full Text] [Related]
9. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: A 12-year-old boy. Hoshino H; Shirai Y; Konishi H; Yamamura T; Shimizu N Mult Scler Relat Disord; 2020 Jan; 37():101460. PubMed ID: 31683232 [TBL] [Abstract][Full Text] [Related]
11. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625 [TBL] [Abstract][Full Text] [Related]
12. Pregnancy and multiple sclerosis: the children of PRIMS. Vukusic S; Confavreux C Clin Neurol Neurosurg; 2006 Mar; 108(3):266-70. PubMed ID: 16413965 [TBL] [Abstract][Full Text] [Related]
13. Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Cramer SP; Modvig S; Simonsen HJ; Frederiksen JL; Larsson HB Brain; 2015 Sep; 138(Pt 9):2571-83. PubMed ID: 26187333 [TBL] [Abstract][Full Text] [Related]
14. A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum? Shirani A; Wu GF; Giannini C; Cross AH BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29954769 [TBL] [Abstract][Full Text] [Related]
15. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. Farina G; Magliozzi R; Pitteri M; Reynolds R; Rossi S; Gajofatto A; Benedetti MD; Facchiano F; Monaco S; Calabrese M J Neuroinflammation; 2017 Feb; 14(1):40. PubMed ID: 28222766 [TBL] [Abstract][Full Text] [Related]
16. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis in the very young: a case report and review of the literature. Sivaraman I; Moodley M Neurodegener Dis Manag; 2016; 6(1):31-6. PubMed ID: 26782315 [TBL] [Abstract][Full Text] [Related]
18. Predictors of relapse rate in MS clinical trials. Held U; Heigenhauser L; Shang C; Kappos L; Polman C; Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520 [TBL] [Abstract][Full Text] [Related]
19. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. Absinta M; Sati P; Schindler M; Leibovitch EC; Ohayon J; Wu T; Meani A; Filippi M; Jacobson S; Cortese IC; Reich DS J Clin Invest; 2016 Jul; 126(7):2597-609. PubMed ID: 27270171 [TBL] [Abstract][Full Text] [Related]
20. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Chowdhury SA; Lin J; Sadiq SA Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]